Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Northwestern University
Study ID
NCT05719714
Phase
PHASE1/PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin 10 MG [Farxiga] — DRUG
    10mg (milligram) tablet to be taken orally once daily for 6 months. Manufacturer: Astrazeneca. Study drug will be stored and dispensed by the Interventional Drug Service Pharmacy at Northwestern University.

Study Details

The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients with chronic kidney disease.

Key Dates

First listed
Feb 9, 2023
Start date
Jan 16, 2024
Status verified
Jul 2025
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
18 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Intervention group
    Thirty individuals will be randomized to dapagliflozin 10mg to be taken daily for six months.
  • No Intervention: Standard of Care group
    Thirty individuals will be randomized to standard of care treatment.

Primary Outcome Measure

Left ventricular longitudinal strain (LVLS) [ Time Frame: 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Northwestern UniversityChicagoIllinois60607-

Find similar trials in Chicago, IL

Nationwide
Heart failure trialsCardiology trialsHeart disease trials
By condition
Heart failure
By specialty
CardiologyHeart disease
By research site
Northwestern University· Chicago, IL

Related Studies